10-Q: Stereotaxis Reports Q2 Revenue Surge, Advances Product Line

Stereotaxis, Inc. reported a significant increase in second-quarter revenue driven by system sales and disposable products, alongside progress in regulatory approvals for its robotic navigation systems and catheters, despite ongoing net losses and macroeconomic headwinds.

Summary

• Total revenue for the six months ended June 30, 2025, increased by approximately 43% to $16.270 million, up from $11.382 million in the prior year period.
• System sales revenue rose to $5.002 million for the six months ended June 30, 2025, compared to $2.852 million in the same period of 2024.
• Revenue from disposables, service, and accessories increased by approximately 32% to $11.268 million for the six months ended June 30, 2025, from $8.530 million in 2024.
• Gross margin percentage decreased to 53% for the six months ended June 30, 2025, from 64% in the prior year, primarily due to changes in product mix and acquisition-related accounting.
• Net loss for the six months ended June 30, 2025, was $9.649 million, an improvement from a net loss of $10.340 million in the same period of 2024.
• Cumulative net losses reached approximately $571.4 million as of June 30, 2025.
• Cash and cash equivalents stood at $6.967 million as of June 30, 2025, down from $12.217 million at December 31, 2024.
• Working capital decreased to $1.2 million as of June 30, 2025, from $4.8 million at December 31, 2024.
• The acquisition of Access Point Technologies EP, Inc. (APT) on July 31, 2024, contributed $2.562 million in revenue and a net loss of $1.395 million for the six months ended June 30, 2025.
• A registered direct offering completed on July 18, 2025, raised gross proceeds of $8.5 million, with an additional $4.0 million expected by November 25, 2025.

Sentiment

Score: 6

Explanation: The company demonstrated strong revenue growth and made significant progress in regulatory approvals for key products, including the GenesisX RMN System in Europe and China, and the MAGiC Sweep catheter in the U.S. The recent capital raise provides necessary liquidity. However, the company continues to incur substantial net losses, gross margins have declined as a percentage of revenue, and it faces ongoing macroeconomic and supply chain risks. The positive developments in product commercialization and market access are tempered by persistent financial challenges and external uncertainties.

Positives

• Total revenue increased significantly by 43% for the six months ended June 30, 2025, demonstrating strong sales growth.
• System sales showed substantial growth, increasing from $2.852 million to $5.002 million year-over-year.
• Disposable, service, and accessories revenue also grew by 32%, indicating increased utilization of existing systems and successful integration of acquired product lines.
• Net loss decreased to $9.649 million from $10.340 million, showing a slight improvement in profitability despite increased operating expenses.
• Successful acquisition of Access Point Technologies EP, Inc. (APT) provides in-house catheter development and manufacturing expertise, enhancing innovation efforts.
• Attained CE Mark for the GenesisX RMN System in Q3 2024, expanding market access in Europe.
• Received China NMPA regulatory approval for the Genesis RMN system in November 2024, opening a significant market.
• Obtained CE marking for the Stereotaxis MAGiC catheter in Europe during Q1 2025.
• Received U.S. FDA 510(k) clearance for the MAGiC Sweep catheter in July 2025, marking a key regulatory milestone for a new product.

Negatives

• Gross margin percentage decreased to 53% from 64% for the six months ended June 30, 2025, primarily due to product mix changes and acquisition-related accounting.
• The company continues to incur significant net losses, with a cumulative deficit of approximately $571.4 million as of June 30, 2025.
• Cash and cash equivalents decreased by over $5 million from December 31, 2024, to June 30, 2025, indicating continued cash burn from operations.
• Working capital significantly declined from $4.8 million to $1.2 million, reducing short-term liquidity.
• Operating expenses increased by approximately 3% for the six months ended June 30, 2025, driven by higher sales and marketing, and general and administrative costs.
• The revaluation of contingent consideration related to the APT acquisition resulted in a $458k expense in General and Administrative expenses.

Risks

• The global tariff environment remains fluid, with potential expiration of U.S.-China tariffs, proposed universal baseline tariff increases, and U.S.-EU negotiations, which could materially affect cost structure, gross margins, and product launch timing.
• Macroeconomic and geopolitical factors, including new or modified tariffs, trade barriers, supply chain challenges, inflationary pressures, elevated interest rates, and conflicts (e.g., Middle East), could adversely impact operations and liquidity.
• Ongoing worldwide supply chain disruptions, including shortages, inflationary pressures, and logistics delays, make it difficult to source parts and ship products.
• Inability to raise product prices sufficiently to keep pace with inflation, particularly tariff-induced inflation, could negatively impact financial performance.
• Material interruptions in manufacturing operations or supply chains could prevent timely production or servicing of products at required levels.
• Hospital customers face staffing and cost pressures, liquidity concerns due to elevated interest rates, which could cause delays or cancellations of purchase orders, longer sales cycles, and decreased demand for disposable products.
• Disruptions to capital markets could negatively impact the company's ability to raise capital or its hospital customers' ability to fund projects, leading to delayed spending or decreased demand.
• Occurrences similar to the COVID-19 pandemic could negatively affect demand for systems and disposable products, leading to business disruptions and reduced procedure volumes.
• Managing APT's catheter manufacturing business is complex and highly technical, with prior experience being dated, posing risks related to supply chain disruptions, labor shortages, and potentially higher overhead.
• The company expects to incur additional losses in 2025 as it continues product development, commercialization, research and development, and sales and marketing initiatives.
• There is no guarantee that additional financing will be available on acceptable terms or that such financing will not be dilutive to stockholders.
• If adequate funds are not available, the company may be required to delay product development/commercialization, license rights to third parties, or reduce sales/marketing/support, potentially leading to a material adverse effect on business or even cessation of operations.
• Regulatory approval processes can be lengthy and uncertain, requiring revised or additional data, and applications could be denied.
• Maintenance of strategic relationships with technology leaders (fluoroscopy, catheters, mapping systems) is critical, and there are no guarantees these relationships will continue or that equivalent alternatives can be obtained on competitive terms.

Future Outlook

The company plans to advance the adoption of its robotic magnetic navigation systems and proprietary devices in markets where regulatory clearance has been received and will continue to seek approvals in other geographies. It expects to incur additional losses in 2025 as it continues product development, commercialization, research and development activities, and sales and marketing initiatives. The company will monitor the impact of the macroeconomic environment on project timing, regulatory approvals, customer and supplier operations, and operating results. Existing cash and cash equivalents, including proceeds from the July 2025 equity raise, are believed to be sufficient to fund operating expenses and capital equipment requirements, but additional funding may be explored, with no assurance of availability on acceptable terms or without dilution.

Management Comments

• We believe the benefits of Robotic Magnetic Navigation can be applicable in other endovascular indications where navigation through complex vasculature is often challenging or unsuccessful and generates significant x-ray exposure, and we are investing in research and development in these areas.
• We are actively developing the next generation imaging and collaboration solutions with Synchrony and SynX.
• We are still integrating the businesses and implementing safeguards to minimize any negative impacts on our financial position, results of operations and cash flows post-acquisition (of APT EP, Inc.).
• We expect to incur additional losses in 2025 as we continue the development and commercialization of our products, conduct our research and development activities, advance new products into clinical development from our existing research programs and fund additional sales and marketing initiatives.
• While we believe our existing cash and cash equivalents, including the proceeds from our July 2025 equity raise, will be sufficient to fund our operating expenses and capital equipment requirements, in light of the macroeconomic environment, we cannot guarantee that we will not need additional funding in the future.

Industry Context

The company operates in the multi-billion-dollar medical device market for cardiac ablation procedures, which is expected to see substantial long-term growth. Its Robotic Magnetic Navigation technology aims to transform endovascular interventions by improving precision, stability, reach, and safety, and reducing x-ray exposure for physicians. The company is expanding its clinical focus beyond electrophysiology to include coronary, neuro, and peripheral interventions, aligning with broader trends in minimally invasive procedures and robotic surgery. The acquisition of APT EP, Inc. and the development of proprietary catheters reflect a strategic move towards vertical integration and control over critical disposable components, a common strategy in the medical device industry to enhance product ecosystems and capture more value.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• A vendor filed financing statements under the Uniform Commercial Code (UCC) on underlying inventory for approximately $0.6 million in February 2024, which the company believes were filed without merit and is fully contesting.

Stakeholder Impact

• Shareholders: Face potential dilution from the recent and upcoming equity raises, but these raises provide necessary capital for operations and growth initiatives. Continued cumulative losses may impact shareholder value.
• Customers (Hospitals): May experience delays in system installations and reduced demand for disposable products due to hospital staffing issues, cost pressures, and liquidity concerns driven by elevated interest rates and macroeconomic factors.
• Employees: Stock-based compensation plans are in place, but macroeconomic factors and supply chain disruptions could impact operational stability and workload.
• Suppliers and Contract Manufacturers: May experience similar difficulties with supply chain disruptions, inflationary pressures, and tariffs, potentially affecting the company's ability to source parts and ship products.
• Creditors: The company has no debt as of June 30, 2025, reducing immediate creditor risk, but ongoing losses and reliance on equity raises for funding are factors.

Next Steps

• Advance adoption of robotic magnetic navigation systems and proprietary devices in markets where regulatory clearance has been received.
• Work with regulatory approval authorities in geographies where approval is pending for products like GenesisX RMN System (U.S.), Stereotaxis MAGiC catheter (U.S. and other geographies), and EMAGIN 5F catheter guide.
• Continue development and commercialization of products.
• Conduct research and development activities.
• Advance new products into clinical development from existing research programs.
• Fund additional sales and marketing initiatives.
• Monitor the impact of the macroeconomic environment on project timing, regulatory approvals, customer and supplier operations, and operating results.
• Continue to explore financing alternatives to fund operations.
• Complete the Additional Closing of the registered direct offering by November 25, 2025, to receive an additional $4.0 million in gross proceeds.
• Continue integrating Access Point Technologies EP, Inc. (APT) and implementing safeguards to minimize negative financial impacts post-acquisition.

Key Dates

Recommendation

While Stereotaxis, Inc. demonstrated strong revenue growth and achieved significant regulatory milestones for its key products, indicating positive momentum in market expansion and product innovation, the company continues to operate at a substantial net loss and has a large accumulated deficit. The recent capital raise provides essential liquidity but is dilutive to existing shareholders. The company faces considerable macroeconomic headwinds, including tariff uncertainties, supply chain disruptions, and hospital financial pressures, which could impact future performance. Given the mixed financial results, the ongoing need for capital, and the inherent risks in a developing medical technology company, a 'hold' recommendation is appropriate. Investors should monitor the company's progress in achieving profitability, managing operational costs, and navigating the complex regulatory and economic environment before considering a stronger position.

Keywords

Robotic Magnetic Navigation, Cardiac Ablation, Electrophysiology, Medical Devices, Interventional Systems, Catheters, Healthcare Technology, SEC Filing, Q2 Earnings, FDA Clearance, CE Mark, Supply Chain, Tariffs, Capital Raise